3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
38
Carcinoma, Non-Small-Cell Lung
23
Lung Neoplasms
10
Neoplasm Metastasis
7
Hodgkin Disease
6
Recurrence
4
Neoplasms
4
Uterine Cervical Neoplasms
3
Sarcoma
2
Rhabdomyosarcoma
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Carcinoma
2
Breast Neoplasms, Male
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Pleural Effusion, Malignant
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non - Small Cell Lung Cancer NSCLC
1
Neuroendocrine Tumors
1
Neuralgia
1
Metatropic dwarfism
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Locally Advanced Non-Small Cell Lung Cancer
1
Lethal Congenital Contracture Syndrome 2
1
Glioma
1
Interventions
Vinorelbine
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Metatropic dwarfism
×
Vinorelbine
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts